Barinthus Biotherapeutics PLC Sustainability Reports

A clinical-stage biopharmaceutical company developing novel antigen-specific immunotherapies to treat chronic viral infections, autoimmune diseases, and cancer.

Sector: Professional & technical services

Country: United Kingdom

Exchange: Nasdaq

LEI: 213800KQ9EAOKPWN8A33

FIGI: BBG00ZZPCPV5

5 reports from 2021 to 2024

• Barinthus Biotherapeutics PLC 2024 Annual Report and Financial Statements
• Barinthus Biotherapeutics PLC 2024 Annual Report
• Barinthus Biotherapeutics PLC 2023 Annual Report and Financial Statements
• Barinthus Biotherapeutics PLC 2022 Annual Report and Financial Statements
• Barinthus Biotherapeutics PLC 2021 Annual Report and Accounts